Trial Profile
Efficacy of intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 09 Dec 2015 New trial record